TETRA BIO-PHARMA WKN: A2ASQ8 ISIN: CA88166Y1007 Kürzel: TBP Forum: Aktien Thema: Hauptdiskussion

Das war ein Spaß. Bin hoch investiert hier. Der horizontale Verlauf ist zwar anstrengend aber hier geht es eh wieder hoch. Keine Sorge.

Ich kann dir nur meine ganz eigene Meinung kundtun

Bei sowas sollte keiner und schon gar nicht in sonem Forum hier, deine Einstellungen beeinflussen.

Vertraue nicht mir, sondern dir und deinem Gefühl

Ich vertrau dir da mal 🙄

Kommt der Tag der Tage, dürfte es uns alle überraschen wie schnell sich Dinge ändern können 🚀😉

Geduld ist hier gefragt. So wie bei allen Bio Pharma

Einfach keine großen Bewegungen hier, leider.

Stark

https://ceo.ca/@nasdaq/tetra-bio-pharmas-recently-acquired-wholly-owned

Ein bisschen was zu lesen aus einer meiner anderen Quellen. "Reviewing PPP005 this morning and comparing with a similar trial being completed by MedReleaf. Clearly I am biased towards Tetra, but wow. I didn’t realize how in-depth 005 was. —————————————————— PPP005: 160 patients (phase 2 data currently being compiled / reviewed) MedReleaf (NCT03522467): 40 patients (in phase 2) —————————————————— Summary of 005: Seeking for effective therapeutic strategies, the investigators are proposing to: -test the effectiveness of different formulations of medical cannabis oil to alleviate chronic pain, which was partially relieved with conventional prescriptions. -assess the effect of different formulations of medical cannabis oil on other symptoms associated to chronic pain: -anxiety -depression -insomnia -appetite -the investigators will examine the safety profile of different cannabis formulations focusing on: -a real chronic administration with more than two weeks of treatment -larger number of patients -clinical relevance of medical cannabis oil to change the amount and type of concomitant medications used to control chronic non-cancer and cancer pain (Summary of MedReleaf: Over a 1-2 year period, 40 cancer patients experiencing poorly controlled pain will be enrolled in to a prospective single-arm cohort study, in which they will receive an orally administered cannabis oil formulation as an add-on therapy to current treatment regimens. Subjects entering the acute study phase will be titrated to a tolerated dose at which a sustained pain response is reached, and may subsequently enter a 12 week chronic phase during which safety and durability of pain response will be assessed at their stable dose) —————————————————— Drugs Tested: Group A: THC/CBD ratio 1:1 capsule Group B: THC/CBD ratio 1:2 capsule Group C: THC/CBD ratio 0.1:2 capsule Group D: Placebo capsule Patients will have a dose titration phase during the first week. The dose escalation will allow patients to adapt to the potential adverse effects (AEs) of the medical cannabis. —————————————————— Questions that 005 is hoping to answer: -Does the daily use of cannabis oil improves chronic pain? -Does the daily use of cannabis oil improves chronic pain ? -Does the daily use of cannabis oil improve symptom burden ? -Does the daily use of cannabis oil reduce the severity of Treatment-Emergent Adverse Events (safety and tolerability) ? -Does the daily use of cannabis oil improve cognition? -Does the daily use of cannabis oil reduce the Profile of Mood States? -Does the daily use of cannabis oil improve the Hamilton Rating Scale for Depression (HAM-D)? -Does the daily use of cannabis oil improve Medication Quantification Scale (MQS) version III? —————————————————— Seeing 005 laid out like this really drives home how thorough Tetra were with this study and how come it’s anticipated to take 6 months to review and compile the data. Wow. I cannot wait to see what the results show. Remember, 005 was Dr Chamberland’s no-brainer trial to run 😇🙂💚"

Gebe ich dir recht. Ein wenig wundere ich mich auch

Nimmt noch nicht so recht Fahrt auf. Eigentlich komisch, bei den vielen positiven Meldungen in letzter Zeit.

Okay. Verstehe

Anfang 2018.

Bisschen länger oder du hast im letzten Peak gekauft